Series C · Biotech · Copenhagen, Denmark · Founded 2019 · 40–60 employees
Hemab Therapeutics is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. The company is advancing breakthrough treatments for rare conditions like Glanzmann Thrombasthenia and Von Willebrand Disease where no preventative options currently exist. Their lead asset sutacimig has received FDA Breakthrough Therapy Designation and is progressing through Phase 2 trials. The company has raised $157 million in Series C funding in October 2025, bringing total funding to approximately $347 million, demonstrating strong investor confidence in their innovative approach to transforming treatment paradigms for blood clotting disorders.